Lung adenocarcinoma (LAC) is currently the predominant histological subtype of NSCLC [2] with an average 5-year survival rate of 15 % despite using epidermal growth factor receptor (EGFR)-targeted therapies. This evidence concerns the gene EGFR and lung adenocarcinoma.